Daniel L. Flynn

Biochemistry, Genetics and Molecular BiologyChemistryMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors”.

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Communications Biology(2020)10.1038/s42003-020-01508-w

N/A

2.2DataRank · unranked

63 citations

Nicolle E. Hofmann, Bryan D. Smith, Igor Odintsov, Morana Vojnic, Irina Linkov +10 more

Hydroxychloroquine in Stage 1 Type 1 Diabetes

Diabetes Care(2023)10.2337/dc23-1096

N/A

0DataRank · unranked

16 citations

Polly J. Bingley, Dorothy J. Becker, Jane H. Buckner, Linda A. DiMeglio, Stephen E. Gitelman +58 more

Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer

eLife(2024)10.7554/elife.96992

N/A

0DataRank · unranked

13 citations

Kayla O’Toole, Sanjana Srinivas Boggaram, Michael T. Scherzer, Mark R. Silvis, Yun Zhang +8 more

Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2464

N/A

0DataRank · unranked

9 citations

Daniel L. Flynn, Cynthia B. Leary, Sun Young Oh, Xiaonan Xue, Maja H. Oktay +3 more

Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.02.06.579200

N/A

0DataRank · unranked

3 citations

Kayla O’Toole, Sanjana Srinivas Boggaram, Michael T. Scherzer, Mark R. Silvis, Yun Zhang +8 more